Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 5
1983 4
1984 7
1985 7
1986 9
1987 17
1988 17
1989 16
1990 28
1991 45
1992 35
1993 65
1994 86
1995 81
1996 95
1997 83
1998 91
1999 68
2000 71
2001 86
2002 69
2003 84
2004 96
2005 87
2006 96
2007 143
2008 142
2009 145
2010 126
2011 117
2012 130
2013 108
2014 123
2015 114
2016 90
2017 96
2018 78
2019 46
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

2,606 results
Results by year
Filters applied: . Clear all
Page 1
Cholesteryl ester transfer protein (CETP), HDL capacity of receiving cholesterol and status of inflammatory cytokines in patients with severe heart failure.
Martinelli AEM, Maranhão RC, Carvalho PO, Freitas FR, Silva BMO, Curiati MNC, Kalil Filho R, Pereira-Barretto AC. Martinelli AEM, et al. Lipids Health Dis. 2018 Oct 20;17(1):242. doi: 10.1186/s12944-018-0888-0. Lipids Health Dis. 2018. PMID: 30342531 Free PMC article.
HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men.
Talbot CPJ, Plat J, Joris PJ, Konings M, Kusters YHAM, Schalkwijk CG, Ritsch A, Mensink RP. Talbot CPJ, et al. Atherosclerosis. 2018 Jul;274:23-28. doi: 10.1016/j.atherosclerosis.2018.04.029. Epub 2018 Apr 28. Atherosclerosis. 2018. PMID: 29747087 Clinical Trial.
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. HPS3/TIMI55–REVEAL Collaborative Group, et al. N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28. N Engl J Med. 2017. PMID: 28847206 Free article. Clinical Trial.
Lipid management in patients with chronic kidney disease.
Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C. Ferro CJ, et al. Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Nat Rev Nephrol. 2018. PMID: 30361677 Review.
Simultaneous Determination of Biliary and Intestinal Cholesterol Secretion Reveals That CETP (Cholesteryl Ester Transfer Protein) Alters Elimination Route in Mice.
Li J, Pijut SS, Wang Y, Ji A, Kaur R, Temel RE, van der Westhuyzen DR, Graf GA. Li J, et al. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):1986-1995. doi: 10.1161/ATVBAHA.119.312952. Epub 2019 Aug 29. Arterioscler Thromb Vasc Biol. 2019. PMID: 31462090
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Free article. Clinical Trial.
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
Arsenault BJ, Petrides F, Tabet F, Bao W, Hovingh GK, Boekholdt SM, Ramin-Mangata S, Meilhac O, DeMicco D, Rye KA, Waters DD, Kastelein JJP, Barter P, Lambert G. Arsenault BJ, et al. J Clin Lipidol. 2018 Jan-Feb;12(1):130-136. doi: 10.1016/j.jacl.2017.10.001. Epub 2017 Oct 12. J Clin Lipidol. 2018. PMID: 29103916 Free article. Clinical Trial.
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Hovingh GK, et al. Lancet. 2015 Aug 1;386(9992):452-60. doi: 10.1016/S0140-6736(15)60158-1. Epub 2015 Jun 2. Lancet. 2015. PMID: 26047975 Clinical Trial.
2,606 results
Jump to page
Feedback